Diabetic Kidney Disease: Pathophysiology and Emerging Therapies

Maradona Bricks^*
*Correspondence: Maradona Bricks, Department of Diabetes and Endocrinology, University of Medicine, Tirana, Albania, Email:

Introduction

Diabetic Kidney Disease (DKD), a complication of both type 1 and type 2 diabetes, is a leading cause of End-Stage Renal Disease (ESRD) worldwide. It presents a significant health burden due to its progressive nature and associated morbidity and mortality. However, recent years have witnessed remarkable advances in understanding the pathophysiology of DKD and the development of novel therapeutic strategies aimed at slowing its progression. This article aims to explore these recent advances and their implications for the management of DKD. DKD is characterized by a spectrum of structural and functional abnormalities in the kidneys, including glomerular hyperfiltration, glomerular basement membrane thickening, mesangial expansion, podocyte injury and tubulointerstitial fibrosis [1]. The underlying mechanisms involve a complex interplay of hemodynamic, metabolic and inflammatory pathways, triggered by chronic hyperglycemia, dyslipidemia, hypertension and genetic factors [2].

Renin-angiotensin-aldosterone system inhibitors, such as Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs), have long been the cornerstone of DKD management. Recent trials, such as the credence and DAPA-CKD trials, have demonstrated the efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in reducing the risk of kidney failure and cardiovascular events in patients with DKD, independent of their glucose-lowering effects. These agents exert renal protective effects through mechanisms including hemodynamic effects, reduction of intraglomerular pressure, anti-inflammatory actions and modulation of tubuloglomerular feedback [3]. Emerging therapies targeting novel pathways implicated in DKD pathogenesis are under investigation. These include endothelin receptor antagonists, mineralocorticoid receptor antagonists and anti-inflammatory agents. The potential of these agents to complement existing treatments and further reduce renal and cardiovascular risk in DKD warrants further exploration through ongoing clinical trials.

Description

The advent of precision medicine has opened avenues for personalized management strategies in DKD. Biomarkers such as Urinary Albumin-to-Creatinine Ratio (UACR), estimated Glomerular Filtration rate (eGFR) and novel biomarkers like kidney injury molecule-1 (KIM-1) and soluble urokinase plasminogen activator receptor (suPAR) enable risk stratification and early detection of DKD progression. This facilitates targeted interventions and individualized treatment plans tailored to patients' specific risk profiles and disease trajectories. Lifestyle interventions, including dietary modifications, weight management, smoking cessation and regular physical activity, play a crucial role in DKD management by addressing modifiable risk factors such as obesity, hypertension and dyslipidemia. Multidisciplinary care models incorporating collaboration between nephrologists, endocrinologists, dietitians, pharmacists and other healthcare professionals are essential for optimizing patient outcomes through comprehensive risk factor management, medication adherence support, patient education and psychosocial support [4].

The integration of telemedicine and digital health solutions into DKD management holds promise for enhancing access to care, monitoring disease progression, promoting self-management and facilitating remote patient-provider communication. Telemonitoring of vital signs, mobile health applications for medication reminders and lifestyle tracking, virtual consultations and electronic health record integration empower patients to actively engage in their care while enabling healthcare providers to deliver timely interventions and monitor treatment efficacy remotely [5].

Conclusion

Recent advances in the management of DKD have transformed the landscape of care, offering new opportunities to slow disease progression, reduce morbidity and mortality and improve the quality of life for patients with DKD. From the refinement of traditional therapies to the development of innovative treatment modalities and the integration of precision medicine and digital health solutions, the evolving paradigm of DKD management emphasizes a personalized, multidisciplinary approach aimed at addressing the complex pathophysiology of the disease and optimizing patient outcomes. As research continues to elucidate the underlying mechanisms of DKD and identify novel therapeutic targets, ongoing collaboration between researchers, clinicians, policymakers and patients is essential to translate these advances into clinical practice and mitigate the global burden of DKD.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Sher, Emina Karahmet, Amina Džidić Krivić, Alma Karahmet and Merima Beca-Zeco, et al. “Novel therapeutical approaches based on neurobiological and genetic strategies for diabetic polyneuropathy-a review.” Diabetes Metab Syndr Clin Res Rev (2023): 102901.

Google Scholar, Crossref, Indexed at

2. Köttgen, Anna, Shih-Jen Hwang, Martin G. Larson and Jennifer E. Van Eyk, et al. “Uromodulin levels associate with a common UMOD variant and risk for incident CKD.” J Am Soc Nephrol 21 (2010): 337-344.

Google Scholar, Crossref, Indexed at

3. Jager, Kitty J., Csaba Kovesdy, Robyn Langham and Mark Rosenberg, et al. “A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases.” Nephrol Dial Transplant 34 (2019): 1803-1805.

Google Scholar, Crossref, Indexed at

4. Alicic, Radica Z., Michele T. Rooney and Katherine R. Tuttle. “Diabetic kidney disease: Challenges, progress and possibilities.” Clin j Am Soc Nephrol 12 (2017): 2032-2045.

Google Scholar, Crossref, Indexed at

5. Freeman, Roy. “Not all neuropathy in diabetes is of diabetic etiology: Differential diagnosis of diabetic neuropathy.” Curr Diabetes Rep 9 (2009): 423-431.

Google Scholar, Crossref, Indexed at